13 completed, 3 unknown, 2 terminated, 1 not yet recruiting. 8 Phase 2, 6 Phase 3, 4 Not applicable, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Unknown 2, Not yet recruiting 1 |
| Phase 3 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Not applicable | 4 | Completed 3, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Withdrawn 1 |
Follow Solvents: new trials by email Literature Review of Solvents trials Research Report on Solvents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study) alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion), Placebo - Acute Exacerbation Chronic Obstructive Pulmonary Disease | Phase 2 | Not yet recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 36 | 2025-10-01 | 2025-08-24 |
| Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride - Pneumonia, Myocardial Injury | Phase 3 | Unknown | Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | 178 | 2024-06-25 | 2024-11-27 |
| Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19), Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) - Covid19 | Phase 1 / Phase 2 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 100 | 2020-07-27 | 2022-03-16 |
| Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution. - Cystic Fibrosis | Phase 1 | Completed | Neupharma Srl | 12 | 2019-10-25 | 2020-12-09 |
| Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen) - Infertility | Phase 3 | Completed | Ferring Pharmaceuticals | 405 | 2019-10-25 | 2023-11-07 |
| Gutta-percha Solvent on Postoperative Pain After Root Canal Retreatment solvent, non-solvent - Postoperative Pain, Root Canal | Not applicable | Completed | Mahidol University | 60 | 2019-09-18 | 2021-09-21 |
| Efficacy and Safety of TISSEEL Lyo Compared to Manual Compression as an Adjunct to Haemostasis TISSEEL Lyo, Manual compression with surgical gauze pads - Adjunct to Hemostasis During Vascular Surgery | Phase 3 | Completed | Baxter Healthcare Corporation | 104 | 2019-07-10 | 2019-12-06 |
| The Effect of Solvent Usage on Post-treatment Pain Non-solvent, Solvent - Root Canal Infection, Pain | Not applicable | Completed | Yuzuncu Yil University | 90 | 2018-10-22 | 2019-07-08 |
| A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine - Virus Diseases | Phase 2 | Completed | GlaxoSmithKline | 600 | 2015-11-09 | 2018-05-03 |
| GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study Triptorelin - Normal Oocyte Donors | Not applicable | Completed | Vietnam National University | 165 | 2014-08-01 | 2017-02-06 |
| The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation Ilomedin - Diabetes, Arteriosclerosis | Phase 2 | Unknown | Prim PD Dr Afshin Assadian | 100 | 2012-10-01 | 2018-10-17 |
| Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Octaplas infusion and placebo (group 1), Octaplas infusion and placebo (group 2) - Purpura, Thrombotic Thrombocytopenic | Phase 4 | Withdrawn | St. Olavs Hospital | 2012-09-01 | 2012-12-21 | |
| Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer SonoVue - Prostate Cancer | Not applicable | Terminated | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 208 | 2011-11-01 | 2016-07-06 |
| Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency Hydrocortisone intramuscular first, Hydrocortisone subcutaneously first - Primary Adrenal Insufficiency | Phase 2 | Completed | Bruno Allolio | 12 | 2011-11-01 | 2012-08-01 |
| Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma Solvent with specific gravity less than lipiodol, Solvent with specific gravity equivalent to lipiodol - Hepatocellular Carcinoma | Phase 3 | Completed | Sun Yat-sen University | 812 | 2011-01-01 | 2019-03-06 |
| FS VH S/D 500 S-apr in Vascular Surgery Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads - Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses | Phase 3 | Completed | Baxter Healthcare Corporation | 176 | 2009-07-01 | 2012-11-27 |
| Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS) Skin test panel and desensitization kit, Skin test panel and solvent - Premenstrual Syndrome | Phase 2 | Unknown | EVE Medical Systems Ltd. | 20 | 2009-04-01 | 2010-06-16 |
| Fibrin Sealant for the Sealing of Dura Sutures Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care - Pathological Processes in the Posterior Fossa, Dura Defects | Phase 2 | Completed | Baxter Healthcare Corporation | 95 | 2008-05-01 | 2013-06-27 |
| Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Uniplas, Cryosupernatant plasma - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Terminated | Octapharma | 8 | 2007-05-01 | 2017-06-21 |
| Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution, Gammagard S/D (Solvent/Detergent) - Primary Immunodeficiency Diseases (PID), Agammaglobulinemia | Phase 2 | Completed | Baxalta now part of Shire | 24 | 2002-06-13 | 2021-08-24 |
Pain, Postoperative (2) · Purpura, Thrombotic Thrombocytopenic (2) · Addison Disease (1) · Adrenal Insufficiency (1) · Agammaglobulinemia (1) · Arteriosclerosis (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Cystic Fibrosis (1) · Diabetes Mellitus (1) · Hemostatic Disorders (1) · Infertility (1) · Liver Neoplasms (1) · Pain (1) · Peripheral Arterial Occlusive Disease 1 (1)
Baxter Healthcare Corporation (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Baxalta now part of Shire (1) · Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica (1) · Bruno Allolio (1) · EVE Medical Systems Ltd. (1) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (1) · Ferring Pharmaceuticals (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · GlaxoSmithKline (1) · Mahidol University (1) · Neupharma Srl (1) · Octapharma (1) · Prim PD Dr Afshin Assadian (1) · St. Olavs Hospital (1)
United States (4) · Italy (3) · Russia (2) · Austria (1) · Canada (1) · China (1) · Finland (1) · Germany (1) · Israel (1) · Mali (1) · Netherlands (1) · Senegal (1) · Sweden (1) · Thailand (1) · Turkey (Türkiye) (1)
Afshin Assadian, Prim PD Dr (1) · Ali G Erdemir (1) · Anne S von Krogh, MD (1) · Duangrat Sirijindamai, DDS (1) · Giulia Paiola, MD (1) · Guenter Zuelow, MD (1) · H. Wijkstra, Prof. Dr. Ir. (1) · Isabella Presch, MD, MBA (1) · Jacob Cohen, Dr. (1) · Lan TN Vuong, MD (1) · Ming Shi (1) · Noemi Evangelisti (1) · Ozgur G Genc Sen (1)
PMID 31093742, PMID 10465169, PMID 10933492, PMID 11148177, PMID 11874817, PMID 11981766, PMID 12045122, PMID 12049862, PMID 12740257, PMID 12826636, PMID 1320447, PMID 15050036, PMID 15683545, PMID 16250051, PMID 18295692, PMID 18507107, PMID 18565211, PMID 19197072, PMID 19553648, PMID 19721826, PMID 19845686, PMID 20843247, PMID 21060150, PMID 21367592, PMID 21486454, PMID 21680942, PMID 22123804, PMID 22447964, PMID 22634722, PMID 23382062, PMID 23526215, PMID 23672956, PMID 23975926, PMID 23989916, PMID 25299856, PMID 25754526, PMID 26026936, PMID 26282478, PMID 26304913, PMID 26523330, PMID 27564664, PMID 27916480, PMID 28162017, PMID 28404617, PMID 29396645, PMID 29719508, PMID 30237305, PMID 3031724, PMID 30965011, PMID 31179005
2014 (1)